Document Detail

Aliskiren in hypertension: evidence for its potential therapeutic value.
MedLine Citation:
PMID:  22496673     Owner:  NLM     Status:  PubMed-not-MEDLINE    
INTRODUCTION: Aliskiren is the first in a new class of antihypertensive drugs that inhibits the conversion of angiotensinogen to angiotensin I by renin, thereby inhibiting production of angiotensin II, the key mediator in the regulation of body fluid volume and blood pressure. Aliskiren is currently in phase III trials as monotherapy and phase II as combination therapy in patients with mild-to-moderate hypertension, and in phase II trials in patients with diabetic nephropathy.
AIMS: The aim of this review is to evaluate the emerging evidence for use of aliskiren in patients with hypertension and to predict its preliminary place in therapy in clinical outcome terms. All randomized, controlled clinical trials of aliskiren (evidence level 2) were included for analysis of efficacy with the selected outcomes of blood pressure lowering, tolerability, and adherence; all other publications were excluded.
EVIDENCE REVIEW: The available level 2 evidence, although limited to phase II trials, suggests that aliskiren is effective at lowering blood pressure, an accepted surrogate outcome of morbidity and mortality, in patients with mild-to-moderate uncomplicated essential hypertension. Preliminary evidence suggests aliskiren is as effective as the angiotensin receptor blocker irbesartan, but more studies are needed. The available evidence also suggests that aliskiren is well tolerated and that patients exhibit good adherence to therapy. Aliskiren's effect on outcomes such as all-cause mortality, reduction in cardiovascular mortality, and reduction in cardiovascular events in patients with mild-to-moderate essential hypertension as well as in special patient populations, remains to be determined.
CLINICAL POTENTIAL: The evidence available regarding aliskiren's effect on outcomes, including blood pressure, tolerability, and adherence, supports its use in patients with mild-to-moderate hypertension. Although there is some preliminary evidence from small pilot trials, the use of aliskiren in combination with other antihypertensives, and the use of aliskiren in other patient populations, cannot be recommended without further evidence.
Doris Peter
Related Documents :
1693193 - Electrophysiological effects of alpha-adrenergic stimulation.
2778713 - A stereoselective central hypotensive action of atenolol.
8021903 - Number of measurements required for the analysis of diurnal blood pressure profile.
Publication Detail:
Type:  Journal Article     Date:  2005-03-31
Journal Detail:
Title:  Core evidence     Volume:  1     ISSN:  1555-1741     ISO Abbreviation:  Core Evid     Publication Date:  2005  
Date Detail:
Created Date:  2012-04-12     Completed Date:  2012-10-02     Revised Date:  2013-08-15    
Medline Journal Info:
Nlm Unique ID:  101256593     Medline TA:  Core Evid     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  13-22     Citation Subset:  -    
Core Medical Publishing, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.
Next Document:  Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmona...